Recent Finacing
Recent Raise
Aro Biotherapeutics develops a Centyrin protein-based targeting platform to deliver siRNA and bispecific therapeutics, advancing tissue-directed genetic medicines and oncology/immunology programs including a Pompe disease candidate.
